# Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study

> **NCT02588781** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 23 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02588781
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2022-12
- **Final completion:** 2023-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588781, "Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02588781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*